Literature DB >> 343894

New drugs in hypertension.

M G Myers.   

Abstract

Clonidine, propranolol, bethanidine and debrisoquine effectively decrease blood pressure by suppressing renin secretion or interfering with function of the sympathetic nervous system. In man these compounds exert an antihypertensive effect within several hours or days and their duration of action is sufficient to permit administration twice or thrice daily. Clonidine and propranolol are especially useful if sexual dysfunction or postural hypotension is undesirable. Although bethanidine and debrisoquine may produce these adverse effects, they are beneficial in severe hypertension and produce fewer side effects than guanethidine. Clonidine frequently causes sedation, and rebound hypertension may occur with sudden cessation of therapy. Injudicious use of propranolol may provoke heart failure or asthma in susceptible individuals. The combination of a thiazide diuretic with propranolol and one of hydralazine, bethanidine and debrisoquine may be used to treat severe or complicated hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 343894      PMCID: PMC1879000     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  26 in total

1.  Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison.

Authors:  B N Prichard; A W Johnston; I D Hill; M L Rosenheim
Journal:  Br Med J       Date:  1968-01-20

Review 2.  The mechanisms of action of some antihypertensive drugs.

Authors:  R Laverty
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

Review 3.  Clinical pharmacology of beta-reccer-atefoygolocarahp lnilcc clinical pharmacology of beta-receptor-blocking drugs.

Authors:  C T Dollery; J W Paterson; M E Conolly
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

4.  Plasma renin and blood pressure during treatment with methyldopa.

Authors:  P Weidmann; D Hirsch; M H Maxwell; R Okun; P Schroth
Journal:  Am J Cardiol       Date:  1974-11       Impact factor: 2.778

5.  Further similarities between the action of clonidine and a central activation of the depressor baroreceptor reflex.

Authors:  G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Cardiovascular effects of intracerebroventricular d-, l- and dl-propranolol in the conscious rabbit.

Authors:  J L Reid; P J Lewis; M G Myers; C T Dollery
Journal:  J Pharmacol Exp Ther       Date:  1974-02       Impact factor: 4.030

7.  Propranolol in hypertension: a study of long-term therapy, 1964-1970.

Authors:  F J Zacharias; K J Cowen; J Prestt; J Vickers; B G Wall
Journal:  Am Heart J       Date:  1972-06       Impact factor: 4.749

8.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

9.  Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man.

Authors:  W A Pettinger; A Korn; H Spiegel; H M Solomon; R Pocelinko; W B Abrams
Journal:  Clin Pharmacol Ther       Date:  1969 Sep-Oct       Impact factor: 6.875

10.  Effects of clonidine withdrawal: possible mechanisms and suggestions for management.

Authors:  S N Hunyor; L Hansson; T S Harrison; S W Hoobler
Journal:  Br Med J       Date:  1973-04-28
View more
  2 in total

1.  Hypokalemia during the treatment of arterial hypertension with diuretics.

Authors:  G Lemieux; M Beauchemin; P Vinay; A Gougoux
Journal:  Can Med Assoc J       Date:  1980-04-19       Impact factor: 8.262

2.  Malignant hypertension.

Authors:  E Z Rabin
Journal:  Can Med Assoc J       Date:  1978-04-22       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.